Biocon Gains On Launch Of Generic Version Of Afinitor In The U.S. Market

Shares of Biocon Ltd. rose 1.45% in intraday trade to Rs 370.06 apiece after the company announced the launch of Everolimus tablets, a generic version of Afinitor in the U.S., thereby expanding its generic formulations portfolio.

Everolimus tablets, a prescription drug used to treat certain types of cancers, have been introduced in four doses. According to IQVIA, U.S. sales of Everolimus tablets was approximately $675 million in the 12 months ending July 2021.

सोशल मीडिया अपडेट्स के लिए हमें Facebook ( https://www.facebook.com/goldsilverreports/ ) और Twitter ( https://twitter.com/goldsilverrepor ) पर फॉलो करें।

हमारी फ्री सर्विस और लोगो की paid सर्विस से कई गुना अच्छी है।
आपको हर दिन दिए जाएंगे 3 से 5 कॉल बिलकुल फ्री
हर CALL में PROFIT दिये जायेंगे

EQUITY CHANNEL को JOIN कर लो (EQUITY FREE TIPS)
JOIN US CLICK HERE

Of the 22 analysts tracking the company, 11 maintained ‘buy’, five maintained ‘hold’ and six maintained ‘sell’ recommendations. The overall consensus price of analysts tracked by Bloomberg implied an upside of 8.3%.

Biocon Gains On Launch Of Generic Version Of Afinitor In The U.S. Market via @goldsilverrepor
  • Save

3 thoughts on “Biocon Gains On Launch Of Generic Version Of Afinitor In The U.S. Market”

Leave a Comment

298 views
Share via
Copy link